BioSensics has launched Nili , a digital health platform designed to support the needs of seniors and patients living independently while minimizing the burden of caregiving. Through a tablet companion, Nili enables aging in place and activities of daily living management for older adults and patients, including individuals with dementia.
Using the Nili Mobile App, multiple care partners can collaborate on managing and coordinating the care of their loved ones.
Nili was developed in collaboration with experts at Baylor College of Medicine and funded by an award of more than $3 million from the National Institutes on Aging (NIA). The platform is based on the latest research in dementia care, including a recent study published in Gerontology .
The study found that coordinated care and support for individuals with dementia and their care partners can improve outcomes and reduce burden. A larger randomized clinical trial is under way (ClinicalTrials.gov Identifier: NCT04308512 ).
BioSensics develops wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare, creating technologies that are now used by thousands of older adults.
The U.S. National Institute of Health (NIH) has awarded BioSensics over $50 million to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.